Business
Premier Biomedical, Inc. Files Patent Application on Cockayne Syndrome Treatment, Which Could Potentially Lead to Major Breakthroughs Against Parkinson's Disease, Alzheimer's Disease and Aging
Premier Biomedical, Inc. Files Patent Application on Cockayne Syndrome Treatment, Which Could Potentially Lead to Major Breakthroughs Against Parkinson's Disease, Alzheimer's Disease and Aging.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\n \n Premier Biomedical, Inc. (OTCQB: \n BIEI) announced that they have filed an application with the U.S. \n Patent Office on a novel approach to the treatment of Cockayne Syndrome.\n \n \n Cockayne Syndrome (CS) is a rare and devastating neurodegenerative \n disorder characterized by slow growth, premature aging (progeria), \n shortened lifespan, moderately to severely inhibited neurological \n development, hearing loss, eye abnormalities/blindness, and sensitivity \n to sunlight. Cockayne Syndrome is caused by an inherited gene mutation.\n \n \n Mitchell S. Felder, M.D., the Chairman of Premier’s Scientific Advisory \n Board, and a board certified attending neurologist, stated, \"The \n physiologic basis of Cockayne Syndrome is a dysfunction in autophagy, \n the intracellular \"cleanup crew\". Recent medical articles have shown \n autophagy to be a major cause of Parkinson's Disease, Alzheimer's \n Disease and aging. I deeply believe that by beating Cockayne Syndrome we \n will also make major therapeutic breakthroughs against Parkinson's \n Disease, Alzheimer's Disease, and even aging. This patent application \n will serve as a detailed and specific roadmap for achieving those major \n breakthroughs.\"\n \n \n About Premier Biomedical, Inc.Premier \n Biomedical, Inc. is a research-based company that intends to discover \n and develop medical treatments for a wide range of diseases in humans. \n Premier has licensed the technology behind multiple patents/patent \n applications in the United States and Europe in the areas of Cancer, \n Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered \n with the Department of Defense with Center of Expertise at the William \n Beaumont Army Medical Center and the University of Texas at El Paso \n (UTEP). The company's R&D efforts are centered in El Paso, TX and their \n business offices are in Western Pennsylvania. The Company's common stock \n trades on the fully reporting Over-The-Counter Bulletin Board under the \n ticker symbol \"BIEI.\"http://www.premierbiomedicalinc.com/\n \n \n Safe Harbor NoticeCertain statements contained \n herein are “forward-looking statements” (as defined in the Private \n Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. \n cautions that statements, and assumptions made in this news release \n constitu...